Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Journal: Gynecologic oncology
Published: June 19, 2021
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 20, 2019
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2019
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Journal: Gynecologic oncology
Published: March 10, 2018
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
Journal: The New England journal of medicine
Published: March 03, 2016
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Journal: Gynecologic oncology
Published: June 12, 2015
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 19, 2014
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Journal: Gynecologic oncology
Published: September 27, 2012
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.
Journal: Gynecologic oncology
Published: February 23, 2012
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Journal: The New England journal of medicine
Published: December 30, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026